Schedule 13G ownership disclosure
AVADEL PHARMACEUTICALS PLC
Common Stock · CUSIP: G29687103
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- JANUS HENDERSON GROUP PLC
Shares: 14,080,219 · Class: 14.6%
- Janus Henderson Biotech Innovation Master Fund Ltd
Shares: 5,203,295 · Class: 5.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001274173-25-000054
- Form type
- SCHEDULE 13G/A
- Filer
- AVADEL PHARMACEUTICALS PLC
- CIK
- CIK 1012477
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership